Login to Your Account

Financings Roundup

Ultragenyx's Rare Disease Focus Attracts $45M in Series A Round

By Jennifer Boggs

Tuesday, June 21, 2011
Proving that big pharma firms aren't the only ones interested in the orphan disease space, venture investors are getting behind 2010 start-up Ultragenyx Pharmaceutical Inc. to the tune of $45 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription